person · Reporting owner
CARPENTER WILLIAM F III
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FB Financial CorpFBK · Entity 4279 | Director | July 31, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FB Financial Corp
Report date July 31, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,981 |
Reported balance
After 2026-07-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-31 · Grant · Acquired 270 · Balance 28,981 F1: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LEGACY LIFEPOINT HEALTH, INC.
Report date November 16, 2018 · Filed November 20, 2018
Section 16 reporting ended · disclosed 2018-11-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-11-16 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2018-11-09 · Gift · Disposed 10,000 · Balance 475,422 Row 2 · 2018-11-13 · Gift · Disposed 36,198 · Balance 439,224 Row 3 · 2018-11-14 · Gift · Disposed 261,539 · Balance 177,685 Row 4 · 2018-11-16 · Disposition to issuer · Disposed 177,685 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger between the Issuer, RegionalCare Hospital Partners Holdings, Inc. d/b/a RCCH HealthCare Partners, and Legend Merger Sub, Inc. (the "Merger Agreement"), each share of Common Stock issued and outstanding immediately prior to the effective time of the merger was canceled and converted into the right to receive $65.00 in cash, without interest. |
| CommonSEC Table I · non-derivative | IndirectBy Retirement Plan | 0 |
Reported balance
After 2018-11-16 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2018-11-16 · Disposition to issuer · Disposed 1,629 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger between the Issuer, RegionalCare Hospital Partners Holdings, Inc. d/b/a RCCH HealthCare Partners, and Legend Merger Sub, Inc. (the "Merger Agreement"), each share of Common Stock issued and outstanding immediately prior to the effective time of the merger was canceled and converted into the right to receive $65.00 in cash, without interest. |
| Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.34 · Expires 2023-02-19 | Direct | 0 |
Reported balance
After 2018-11-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-11-16 · Disposition to issuer · Disposed 200,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. |
| Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.97 · Expires 2022-02-21 | Direct | 0 |
Reported balance
After 2018-11-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-11-16 · Disposition to issuer · Disposed 200,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. |
| Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.51 · Expires 2020-02-23 | Direct | 0 |
Reported balance
After 2018-11-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-11-16 · Disposition to issuer · Disposed 235,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. |
| Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.88 · Expires 2021-02-23 | Direct | 0 |
Reported balance
After 2018-11-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-11-16 · Disposition to issuer · Disposed 165,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. |
| Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.22 · Expires 2026-02-23 | Direct | 0 |
Reported balance
After 2018-11-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-11-16 · Disposition to issuer · Disposed 242,932 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. |
| Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.41 · Expires 2019-02-24 | Direct | 0 |
Reported balance
After 2018-11-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-11-16 · Disposition to issuer · Disposed 200,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. |
| Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.00 · Expires 2025-02-24 | Direct | 0 |
Reported balance
After 2018-11-16 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-11-16 · Disposition to issuer · Disposed 255,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. |
| Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.90 · Expires 2024-02-25 | Direct | 0 |
Reported balance
After 2018-11-16 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2018-11-16 · Disposition to issuer · Disposed 195,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. |
| Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.85 · Expires 2028-02-27 | Direct | 0 |
Reported balance
After 2018-11-16 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2018-11-16 · Disposition to issuer · Disposed 239,167 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. |
| Non-Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.50 · Expires 2027-02-28 | Direct | 0 |
Reported balance
After 2018-11-16 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2018-11-16 · Disposition to issuer · Disposed 245,482 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-11-16 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2018-11-16 · Disposition to issuer · Disposed 198,555 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each outstanding performance-based restricted stock unit ("PRSU"), whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of Common Stock subject to such PRSUs as set forth in the applicable award agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2019-12-31 | Direct | 0 |
Reported balance
After 2018-11-16 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2018-11-16 · Disposition to issuer · Disposed 81,009 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each outstanding performance-based restricted stock unit ("PRSU"), whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of Common Stock subject to such PRSUs as set forth in the applicable award agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger between the Issuer, RegionalCare Hospital Partners Holdings, Inc. d/b/a RCCH HealthCare Partners, and Legend Merger Sub, Inc. (the "Merger Agreement"), each share of Common Stock issued and outstanding immediately prior to the effective time of the merger was canceled and converted into the right to receive $65.00 in cash, without interest.
F2: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration.
F3: Pursuant to the terms of the Merger Agreement, each outstanding performance-based restricted stock unit ("PRSU"), whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of Common Stock subject to such PRSUs as set forth in the applicable award agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 4, 2026 20:37 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 270 | $60.38 | $16,302.60 |
DisclosureSEC source: 0001189136-26-000006 · wk-form4_1785875870.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,981 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| May 22, 2026 Filed May 27, 2026 16:48 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 1,329 | $0.00 | $0.00 |
DisclosureSEC source: 0001189136-26-000004 · wk-form4_1779900505.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,711 F1 · security: Reflects an award of Restricted Stock Units (RSUs) granted pursuant to the issuer's Non-Employee Director Compensation Policy. The RSUs vest on April 30, 2027. Read SEC document |
| April 30, 2026 Filed May 4, 2026 22:05 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 1,758 | $54.07 | $95,055.06 |
DisclosureSEC source: 0001189136-26-000003 · wk-form4_1777932322.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,382 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 18:03 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 261 | $57.53 | $15,015.33 |
DisclosureSEC source: 0001189136-26-000001 · wk-form4_1770141827.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,624 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's FB Financial Corporation Non-Employee Director Compensation Policy. Read SEC document |
| October 31, 2025 Filed Nov 3, 2025 22:01 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 278 | $54.01 | $15,014.78 |
DisclosureSEC source: 0001189136-25-000002 · wk-form4_1762207279.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,363 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's FB Financial Corporation Non-Employee Director Compensation Policy. Read SEC document |
| July 31, 2025 Filed Aug 1, 2025 18:20 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 308 | $48.76 | $15,018.08 |
DisclosureSEC source: 0001649749-25-000185 · wk-form4_1754072394.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,085 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| May 23, 2025 Filed May 28, 2025 16:18 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 1,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001649749-25-000147 · wk-form4_1748449115.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,777 F1 · security: Reflects an award of Restricted Stock Units (RSUs) granted pursuant to the issuer's Non-Employee Director Compensation Policy. The RSUs vest on April 30, 2026. Read SEC document |
| April 30, 2025 Filed May 2, 2025 14:30 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 1,998 | $42.56 | $85,034.88 |
DisclosureSEC source: 0001649749-25-000126 · wk-form4_1746196216.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,401 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 21:31 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 285 | $52.81 | $15,050.85 |
DisclosureSEC source: 0001649749-25-000022 · wk-form4_1738618272.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,403 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| October 31, 2024 Filed Nov 1, 2024 22:04 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 305 | $0.00 | $0.00 |
DisclosureSEC source: 0001649749-24-000195 · wk-form4_1730498665.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,118 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| July 31, 2024 Filed Aug 1, 2024 21:21 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 268 | $0.00 | $0.00 |
DisclosureSEC source: 0001649749-24-000162 · wk-form4_1722547256.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,813 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| May 24, 2024 Filed May 29, 2024 21:31 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 1,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001649749-24-000141 · wk-form4_1717018298.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,545 F1 · security: Reflects an award of Restricted Stock Units (RSUs) granted pursuant to the issuer's Non-Employee Director Compensation Policy. The RSUs vest on April 30, 2025. Read SEC document |
| April 30, 2024 Filed May 1, 2024 23:23 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 1,707 | $36.65 | $62,561.55 |
DisclosureSEC source: 0001649749-24-000113 · wk-form4_1714605776.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,938 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 22:32 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 336 | $37.25 | $12,516.00 |
DisclosureSEC source: 0001649749-24-000025 · wk-form4_1706826735.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,231 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 23:09 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 426 | $29.37 | $12,511.62 |
DisclosureSEC source: 0001649749-23-000248 · wk-form4_1698966548.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,895 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| July 31, 2023 Filed Aug 3, 2023 16:17 UTC | FB Financial Corp FBK · Entity 4279 | PurchaseCommon Stock | 353 | $35.42 | $12,503.26 |
DisclosureSEC source: 0001649749-23-000207 · wk-form4_1691079440.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,469 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| May 19, 2023 Filed May 24, 2023 20:19 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 1,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001649749-23-000168 · wk-form4_1684959579.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,116 F1 · security: Reflects an award of Restricted Stock Units (RSUs) granted pursuant to the issuer's Non-Employee Director Compensation Policy. The RSUs vest on April 30, 2024. Read SEC document |
| April 28, 2023 Filed May 2, 2023 22:07 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 2,124 | $29.43 | $62,509.32 |
DisclosureSEC source: 0001649749-23-000127 · wf-form4_168306522825442.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,283 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| January 31, 2023 Filed Feb 1, 2023 14:43 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 333 | $37.56 | $12,507.48 |
DisclosureSEC source: 0001649749-23-000020 · wf-form4_167526259636288.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,159 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 21:08 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 298 | $41.96 | $12,504.08 |
DisclosureSEC source: 0001649749-22-000175 · wf-form4_166742326168202.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,826 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| July 31, 2022 Filed Aug 1, 2022 21:46 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 292 | $42.85 | $12,512.20 |
DisclosureSEC source: 0001649749-22-000147 · wf-form4_165939032426466.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,528 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| May 20, 2022 Filed May 24, 2022 23:42 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 1,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001649749-22-000117 · wf-form4_165343575292420.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,236 F1 · security: Reflects an award of Restricted Stock Units (RSUs) granted pursuant to the issuer's Non-Employee Director Compensation Policy. The RSUs vest on April 30, 2023. Read SEC document |
| April 30, 2022 Filed May 3, 2022 22:53 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 260 | $38.53 | $10,017.80 |
DisclosureSEC source: 0001649749-22-000088 · wf-form4_165161833541755.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,954 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 01:52 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 225 | $44.52 | $10,017.00 |
DisclosureSEC source: 0001649749-22-000016 · wf-form4_164385313070722.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,694 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| October 29, 2021 Filed Nov 3, 2021 00:16 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 220 | $45.33 | $9,972.60 |
DisclosureSEC source: 0001649749-21-000166 · wf-form4_163589858536654.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,469 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| July 30, 2021 Filed Aug 2, 2021 20:30 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 265 | $37.81 | $10,019.65 |
DisclosureSEC source: 0001649749-21-000129 · wf-form4_162793622425990.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,249 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| May 21, 2021 Filed May 25, 2021 14:35 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 939 | $0.00 | $0.00 |
DisclosureSEC source: 0001649749-21-000109 · wf-form4_162195329634119.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,984 F1 · security: Reflects an award of Restricted Stock Units (RSUs) granted pursuant to the issuer's Non-Employee Director Compensation Policy. The RSUs vest on April 30, 2022. Read SEC document |
| April 30, 2021 Filed May 3, 2021 20:17 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 239 | $41.96 | $10,028.44 |
DisclosureSEC source: 0001649749-21-000089 · wf-form4_162007300988119.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,045 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| January 31, 2021 Filed Feb 1, 2021 22:42 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 268 | $37.36 | $10,012.48 |
DisclosureSEC source: 0001649749-21-000007 · wf-form4_161221935702088.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,806 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's Non-Employee Director Compensation Policy. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 18:32 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 329 | $30.43 | $10,011.47 |
DisclosureSEC source: 0001649749-20-000177 · wf-form4_160442835504568.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,538 F1 · security: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's FB Financial Corporation Non-Employee Director Compensation Policy. Read SEC document |
| July 31, 2020 Filed Aug 3, 2020 18:38 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 394 | $25.41 | $10,011.54 |
DisclosureSEC source: 0001649749-20-000142 · wf-form4_159647988408859.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,209 F1 · acquired: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's FB Financial Corporation Non-Employee Director Compensation Policy. Read SEC document |
| May 06, 2020 Filed May 6, 2020 19:54 UTC | FB Financial Corp FBK · Entity 4279 | PurchaseCommon Stock | 4,547 | $22.35 | $101,625.45 |
DisclosureSEC source: 0001649749-20-000120 · wf-form4_158879484632597.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,815 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.07 to $22.52, inclusive. The reporting person undertakes to provide to FB Financial Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| May 01, 2020 Filed May 4, 2020 23:58 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 1,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001649749-20-000108 · wf-form4_158863668813190.xml · nonDerivative · entry 2 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268 F2 · security: Reflects an award of Restricted Stock Units ("RSUs") granted pursuant to the Policy. The RSUs vest on April 30, 2021. F2 · kind: Reflects an award of Restricted Stock Units ("RSUs") granted pursuant to the Policy. The RSUs vest on April 30, 2021. Read SEC document |
| April 30, 2020 Filed May 4, 2020 23:58 UTC | FB Financial Corp FBK · Entity 4279 | GrantCommon Stock | 448 | $22.34 | $10,008.32 |
DisclosureSEC source: 0001649749-20-000108 · wf-form4_158863668813190.xml · nonDerivative · entry 1 CARPENTER WILLIAM F III · CIK 0001189136 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 448 F1 · kind: This transaction represents stock received by the reporting person in lieu of cash pursuant to the issuer's FB Financial Corporation Non-Employee Director Compensation Policy (the "Policy"). Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:49 UTC | LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283 | Disposition to issuerRestricted Stock Units · Derivative | 81,009 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001225208-18-015767 · doc4.xml · derivative · entry 17 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 81,009 shares Expires 2019-12-31 F3 · derivative.exercise_price: Pursuant to the terms of the Merger Agreement, each outstanding performance-based restricted stock unit ("PRSU"), whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of Common Stock subject to such PRSUs as set forth in the applicable award agreement. F3 · kind: Pursuant to the terms of the Merger Agreement, each outstanding performance-based restricted stock unit ("PRSU"), whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of Common Stock subject to such PRSUs as set forth in the applicable award agreement. F3 · price: Pursuant to the terms of the Merger Agreement, each outstanding performance-based restricted stock unit ("PRSU"), whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of Common Stock subject to such PRSUs as set forth in the applicable award agreement. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding performance-based restricted stock unit ("PRSU"), whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of Common Stock subject to such PRSUs as set forth in the applicable award agreement. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each outstanding performance-based restricted stock unit ("PRSU"), whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of Common Stock subject to such PRSUs as set forth in the applicable award agreement. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:49 UTC | LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283 | Disposition to issuerRestricted Stock Units · Derivative | 198,555 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001225208-18-015767 · doc4.xml · derivative · entry 16 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 198,555 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the terms of the Merger Agreement, each outstanding performance-based restricted stock unit ("PRSU"), whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of Common Stock subject to such PRSUs as set forth in the applicable award agreement. F3 · kind: Pursuant to the terms of the Merger Agreement, each outstanding performance-based restricted stock unit ("PRSU"), whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of Common Stock subject to such PRSUs as set forth in the applicable award agreement. F3 · price: Pursuant to the terms of the Merger Agreement, each outstanding performance-based restricted stock unit ("PRSU"), whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of Common Stock subject to such PRSUs as set forth in the applicable award agreement. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding performance-based restricted stock unit ("PRSU"), whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of Common Stock subject to such PRSUs as set forth in the applicable award agreement. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each outstanding performance-based restricted stock unit ("PRSU"), whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, equal to the merger consideration of $65.00 per share multiplied by the number of shares of Common Stock subject to such PRSUs as set forth in the applicable award agreement. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:49 UTC | LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283 | Disposition to issuerNon-Qualified Stock Options (Right to buy) · Derivative | 245,482 | $0.00 Strike: $64.50 | $0.00 |
DisclosureSEC source: 0001225208-18-015767 · doc4.xml · derivative · entry 15 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 245,482 shares Expires 2027-02-28 F2 · kind: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:49 UTC | LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283 | Disposition to issuerNon-Qualified Stock Options (Right to buy) · Derivative | 239,167 | $0.00 Strike: $44.85 | $0.00 |
DisclosureSEC source: 0001225208-18-015767 · doc4.xml · derivative · entry 14 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 239,167 shares Expires 2028-02-27 F2 · kind: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:49 UTC | LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283 | Disposition to issuerNon-Qualified Stock Options (Right to buy) · Derivative | 195,000 | $0.00 Strike: $52.90 | $0.00 |
DisclosureSEC source: 0001225208-18-015767 · doc4.xml · derivative · entry 13 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 195,000 shares Expires 2024-02-25 F2 · kind: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:49 UTC | LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283 | Disposition to issuerNon-Qualified Stock Options (Right to buy) · Derivative | 255,000 | $0.00 Strike: $71.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015767 · doc4.xml · derivative · entry 12 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 255,000 shares Expires 2025-02-24 F2 · kind: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:49 UTC | LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283 | Disposition to issuerNon-Qualified Stock Options (Right to buy) · Derivative | 200,000 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0001225208-18-015767 · doc4.xml · derivative · entry 11 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 200,000 shares Expires 2019-02-24 F2 · kind: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:49 UTC | LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283 | Disposition to issuerNon-Qualified Stock Options (Right to buy) · Derivative | 242,932 | $0.00 Strike: $64.22 | $0.00 |
DisclosureSEC source: 0001225208-18-015767 · doc4.xml · derivative · entry 10 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 242,932 shares Expires 2026-02-23 F2 · kind: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:49 UTC | LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283 | Disposition to issuerNon-Qualified Stock Options (Right to buy) · Derivative | 165,000 | $0.00 Strike: $35.88 | $0.00 |
DisclosureSEC source: 0001225208-18-015767 · doc4.xml · derivative · entry 9 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 165,000 shares Expires 2021-02-23 F2 · kind: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:49 UTC | LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283 | Disposition to issuerNon-Qualified Stock Options (Right to buy) · Derivative | 235,000 | $0.00 Strike: $31.51 | $0.00 |
DisclosureSEC source: 0001225208-18-015767 · doc4.xml · derivative · entry 8 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 235,000 shares Expires 2020-02-23 F2 · kind: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:49 UTC | LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283 | Disposition to issuerNon-Qualified Stock Options (Right to buy) · Derivative | 200,000 | $0.00 Strike: $39.97 | $0.00 |
DisclosureSEC source: 0001225208-18-015767 · doc4.xml · derivative · entry 7 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 200,000 shares Expires 2022-02-21 F2 · kind: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:49 UTC | LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283 | Disposition to issuerNon-Qualified Stock Options (Right to buy) · Derivative | 200,000 | $0.00 Strike: $44.34 | $0.00 |
DisclosureSEC source: 0001225208-18-015767 · doc4.xml · derivative · entry 6 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common · 200,000 shares Expires 2023-02-19 F2 · kind: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding option, whether vested or unvested, became fully vested as of the effective time of the merger, and was canceled and converted into the right to receive an amount in cash, without interest and less any applicable withholding taxes, determined by multiplying the excess, if any, of the merger consideration of $65.00 per share over the applicable exercise price per share of such option by the number of shares of common stock subject to such option, or if there was no such excess was canceled without consideration. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:49 UTC | LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283 | Disposition to issuerCommon | 1,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015767 · doc4.xml · nonDerivative · entry 5 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Retirement Plan Disclosed balance after: 0 F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger between the Issuer, RegionalCare Hospital Partners Holdings, Inc. d/b/a RCCH HealthCare Partners, and Legend Merger Sub, Inc. (the "Merger Agreement"), each share of Common Stock issued and outstanding immediately prior to the effective time of the merger was canceled and converted into the right to receive $65.00 in cash, without interest. F1 · price: Pursuant to the terms of the Agreement and Plan of Merger between the Issuer, RegionalCare Hospital Partners Holdings, Inc. d/b/a RCCH HealthCare Partners, and Legend Merger Sub, Inc. (the "Merger Agreement"), each share of Common Stock issued and outstanding immediately prior to the effective time of the merger was canceled and converted into the right to receive $65.00 in cash, without interest. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 21:49 UTC | LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283 | Disposition to issuerCommon | 177,685 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015767 · doc4.xml · nonDerivative · entry 4 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the terms of the Agreement and Plan of Merger between the Issuer, RegionalCare Hospital Partners Holdings, Inc. d/b/a RCCH HealthCare Partners, and Legend Merger Sub, Inc. (the "Merger Agreement"), each share of Common Stock issued and outstanding immediately prior to the effective time of the merger was canceled and converted into the right to receive $65.00 in cash, without interest. F1 · price: Pursuant to the terms of the Agreement and Plan of Merger between the Issuer, RegionalCare Hospital Partners Holdings, Inc. d/b/a RCCH HealthCare Partners, and Legend Merger Sub, Inc. (the "Merger Agreement"), each share of Common Stock issued and outstanding immediately prior to the effective time of the merger was canceled and converted into the right to receive $65.00 in cash, without interest. Read SEC document |
| November 14, 2018 Filed Nov 20, 2018 21:49 UTC | LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283 | GiftCommon | 261,539 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015767 · doc4.xml · nonDerivative · entry 3 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,685 Read SEC document |
| November 13, 2018 Filed Nov 20, 2018 21:49 UTC | LEGACY LIFEPOINT HEALTH, INC. LPNT · Entity 162283 | GiftCommon | 36,198 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015767 · doc4.xml · nonDerivative · entry 2 CARPENTER WILLIAM F III · CIK 0001189136 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,224 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.